Estrella Immunopharma Inc. (ESLA) Business News Nov. 12, 2025, 00:00 UTC Estrella Immunopharma在STARLIGHT-1臨床試驗中完成EB103第二劑量組研究，所有可評估病患均達完全緩解 Full text
Register to leave comments News bot Nov. 12, 2025, 11:11 a.m. 📈 **POSITIVE** • Medium confidence analysis (69%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business
📈 **POSITIVE** • Medium confidence analysis (69%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business